drugset / Trial / NCT03283085
A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of long-term treatment with ontamalimab in participants with moderate to severe Ulcerative Colitis (UC) or Crohn's disease (CD)
Timeline
- Start
- 2018-02-27
- Primary completion
- 2023-12-13
- Completion
- 2023-12-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ontamalimab | Monoclonal antibody | 25 mg | Subcutaneous |
| Subject | Ontamalimab | Monoclonal antibody | 75 mg | Subcutaneous |